Transcranial Oncothermia in patients with relapsed high-grade gliomas

Glioma cáncer de cerebro

Transcranial Oncothermia in patients with relapsed high-grade gliomas

Experimental data and retrospective studies suggest potential effects

Dr. Wismeth’s Team of the Department of Neurology of the University of Regensburg, Germany, published in the journal J Neurooncol (J Neurooncol, 2010 Jul; 98 (3): 395-405) the results of the joint use of Oncothermia and chemotherapy used as salvage treatment in the relapse of patients with high-grade gliomas.

Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. A single-center prospective non-controlled single-arm Phase I trial was performed. Main inclusion criteria were recurrent high-grade glioma WHO Grade III or IV, age 18-70, and Karnofsky performance score > or = 70.

Primary endpoints were dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) with the combined regimen. Groups of 3 or 4 patients were treated 2-5 times a week in a dose-escalation scheme with Oncothermia. Alkylating chemotherapy (ACNU, nimustin) was administered at a dose of 90 mg/m(2) on day 1 of 42 days for up to six cycles or until tumor progression (PD) or DLT occurred. Fifteen patients with high-grade gliomas were included.

Relevant toxicities were local pain and increased focal neurological signs or intracranial pressure. No DLT occurred. In some patients, the administration of mannitol during EHT or long-term use of corticosteroids was necessary to resolve symptoms.

Results

Oncothermia in combination with chemotherapy is tolerable in patients with relapse of high-grade gliomas. A Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial.

If you wish, you can find more information about clinical cases treated with Oncotermia on our website.

Clinical Trial in the Treatment of Peritoneal Carcinomatosis (Malignant Ascitis)

Ascitis maligna y OncothermiaClinical trial in the treatment of peritoneal carcinomatosis

Oncothermia and Traditional Chinese Medicine (TCM) versus Chemotherapy

Dr. Pang’s team, Clifford Hospital, Guangzhou, China, recently published in the Molecular Clinical Oncology journal (Mol Clin Oncol, 2017 May; 6 (5): 723-732) the results of the Phase II Clinical Trial on the complementary use of Oncothermia in Peritoneal Carcinomatosis with malignant Ascitis.

The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of Oncothermia combined with the traditional Chinese medicine (TCM) ‘Shi Pi’ herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI).

A randomized, controlled, single-center, open-label clinical trial (phase II) with two parallel groups (allocation ratio, 1:1) was conducted to investigate the efficacy and safety of Oncothermia+TCM (study group, SG) vs. standard IPCI (control group, CG) in patients with PCMA by intention-to-treat analysis.

A total of 260 patients with PCMA were randomly allocated into the two groups (130/130); Oncothermia was applied for 60 min per session every second day for 4 weeks, for a total of 14 sessions. The TCM decoction was administered orally, at 400 ml daily. In CG, occlusive IPCI with cisplatin (30–60 mg) and fluorouracil (500–600 mg/m2) was applied twice, biweekly. The objective response rate (ORR), quality of life (QoL) and adverse event rate (AER) in the two groups were evaluated 1 month after treatment, analyzed and compared.

The present study is registered on ClinicalTrials.gov (NCT02638051). No case was lost or excluded (0/260).

[list type=”check”]

  • The ORR in SG was 77.69% (101/130) vs. 63.85% (73/130) in CG (P<0.05)
  • The QoL in SG was 49.23% vs. 32.3% in CG (P<0.05)
  • The AER in SG was 2.3% (3/130) vs. 12.3% (16/130) in CG (P<0.05)

[/list]

All the adverse events were grade I.

Results

The combination of Oncothermia with TCM achieves better control of PCMA compared with standard IPCI, with less toxicity.

Both components of the combination are non-toxic treatments easily tolerated by patients.

Thus, this combined treatment may be preferred due to the better benefit-harm balance.

If you wish to expand the information regarding Oncotermia applied to cancers, you can visit the following link.

Effect of Oncothermia at the cellular level. Study in colorectal cancer xenografts

Effect of Oncothermia at the cellular level. Study in colorectal cancer xenografts

Researchers studied the effect of Oncothermia at the cellular level in the process of apoptosis in colorectal cancer cells.

The Department of Radiology of the Medicine and Pharmacy Faculty -University of Toyama, in Toyama, Japan- published in the journal CellStress and Chaperones (Springer) (Cell Stress Chaperones, 2015 Jan; 20 (1): 37-46 ) the results on the effect of Oncothermia in colorectal cancer cells.

Cell apoptosis

First of all, the use of modulated electrohyperthermia (mEHT) or Oncothermia, produces a modification of the electric field and the surrounding temperature of the tumor cell, leading to selective cell death (apoptosis) in malignant tumors without affecting healthy tissue. Certainly, this is possible due to the difference of a tumor cell compared with a healthy cell. Also, the tumor cell is characterized by high glycolysis, increased lactate production (Warburg effect) and reduced electrical impedance.

Oncothermia applied to colorectal cancer

Dr Andocs studied the effect of Oncothermia on HT29 xenografts of colorectal cancer (human colon cancer cells, inoculated in mice). Apoptosis caused by Oncothermia was mediated, predominantly, by the caspase cascade and the activation of the apoptosis inducing factor. The mEHT-related cell stresses studied 0-, 1-, 4-, 8-, 14-, 24-, 48-, 72-, 120-, 168- and 216-h. And post-treatment by focusing on damage-associated molecular pattern (DAMP) signals.

 Apoptosis response was after 4 hours from the treatment with Oncothermia. It was measured using the levels of messenger RNA (mRNA) levels of the “heat shock” proteins Hsp70 and Hsp90.

Results

After that, the treatment resulted in spatiotemporal occurrence of a DAMP protein signal sequence featured by the significant cytoplasmic to cell membrane translocation of calreticulin at 4 h, Hsp70 between 14 and 24 h and Hsp90 between 24- and 216-h post-treatment.

Also, the release of high-mobility group box1 protein (HMGB1) from tumor cell nuclei from 24-h post-treatment and its clearance from tumor cells by 48 h was also detected.

Conclusion

In conclusion, the results suggest that mEHT treatment can induce a DAMP-related signal sequence in colorectal cancer xenografts that may be relevant for promoting immunological cell death response, which need to be further tested in immune-competent animals.

To conclude, the next experimental phase, which is to replicate the study in immunocompetent animals, is necessary.

Further information

If you would like further information on Oncothermia applied to colon cancer, please visit the following link.

Oncothermia and the use of oral transmucosal fentanyl citrate

Oncothermia and the use of oral transmucosal fentanyl citrate

Dr. Lee’s team, Department of Oncology, Institute of Clinical Medicine, Chonbuk University, Jeonju, Republic of Korea, published in the journal Clin Ther. 2016 Dec; 38 (12): 2548-2554, results on the safety of the use of Oncothermia and the drug for pain: transmucosal oral fentanyl citrate.

The purpose of this study was to determine if changes occur in the absorption and disposition of the drug fentanyl when it is administered together with the modulated electrohyperthermia treatment (mEHT, Oncothermia).

A randomized, single-dose, crossover, open-label study was used to investigate the effect of Oncothermia on the pharmacokinetic properties of fentanyl in 12 healthy volunteers.

Method

The 12 healthy volunteers were each administered a single dose of oral transmucosal fentanyl citrate (OTFC) or a single dose of OTFC with Oncothermia. Oncothermia was performed on the abdomen for 1 hour. Blood samples were collected for 24 hours after dosing. The temperature of the abdominal skin surface was assessed before dosing and at 10, 20, and 60 minutes after dosing.

Results

There was an increase in the overall exposure to the drug without implications of any clinical significance. OTFC can be administered without limitations in combination with Oncothermia, and it is not necessary to modify the dosing regimen.

For further information on Oncothermia, please visit the following link.

,

Oncothermia at the Congress of Radiotherapy Technicians (10-12 / 11/2017, Lisbon, Portugal)

Oncothermia at the Congress of Radiotherapy Technicians (10-12 / 11/2017, Lisbon, Portugal)

Filipe Cidade de Moura and Prof.András Szász

Oncothermia is an adjuvant treatment for cancer. It is present at an international level at events such as this congress and other conferences. At these scientific meetings, doctors, technicians and healthcare personnel give presentations to disseminate the results of clinical cases.

Congress in Lisboa

Therefore, on November 10-12, 2017, in Lisbon, took place the Congress of Radiotherapy Technicians (Congresso 2017art).

The congress was organized in different sections. Professor Szasz led the talk “Immunological effects with Oncothermia“, where he presented his latest research and results. Also, he detailed his studies on Oncothermia and the results in relation to the inhibitory effect on the natural activity of the malignant cells. Among other things he highlighted the stimulation of the patient’s immune response.

Objective of the research

Most of the radiation therapies act locally. The local control of the tumor is usually not enough for elongation of the survival time because the malignancy is systemic. The abscopal effect, together with immune-stimuli could extend the local method to systemic and could be effective against macro- and micrometastases, too. Our objective is presenting the abscopal effect of modulated electro-hyperthermia (mEHT, oncothermia).

References

https://www.justnews.pt/documentos/2015/image/file/17e/ProgramaCNART-2017.pdf

http://oncotherm.com/en/news-events/congresso-2017-art-profandras-szasz-was-invited-hold-lecture

Oncothermia combined with chemotherapy for the treatment of recurrent cervical cancer

Oncothermia combined with chemotherapy for the treatment of recurrent cervical cancer

Researchers compared the effect of Oncothermia combined with conventional chemotherapy versus chemotherapy alone in patients with cervical cancer.

Cáncer cérvix Oncothermia

Dr. Lee’s team, from Department of Radiation Oncology, Institute of Medical Sciences, Chonbuk Medical University, South Korea, has recently published in the journal Oncology Letters the results on the complementary use of Oncothermia in recurrent Cervix Cancer previously treated with radiotherapy.

The present study was performed to evaluate the effect of Oncothermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation.

Method

A total of 20 patients, aged 36-71 years, with cervical cancer were treated with chemotherapy. Of these, 18 patients were treated with chemotherapy combined with Oncothermia. In addition, the equipment used was: EHY2000 (Oncotherm GmbH, Troisdorf, Germany). And the frequency was 13.56 MHz, with the circular electrode diameter of 30 cm.

In addition, local metastases (including para-aortic lymph nodes and adjacent pelvic lymph nodes) were considered in the inclusion criteria of the study. Also, patients with distant metastases were excluded.

For the study, Oncothermia was applied 3 times a week for 60 minutes from the start of chemotherapy. A total of 36 sessions were carried out.

Results

The overall response (complete remission + partial remission + stable disease/progressive disease) to treatment was significantly greater in the group of patients who underwent chemotherapy combined with Oncothermia (P=0.0461). Then, Oncothermia was shown to be more effective in the treatment of local metastases (lymph nodes). No complications with the use of Oncothermia were reported.

Conclusion

In conclusion, in patients with recurrent cervical cancer treated with radiotherapy, the overall response rate to treatment is significantly higher in patients who combined chemotherapy with Oncothermia compared to those who only received chemotherapy.

Reference

Lee SY, Lee NR, Cho DH, Kim JS. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncol Lett. 2017 Jul;14(1):73-78. doi: 10.3892/ol.2017.6117. Epub 2017 May 4. PMID: 28693137; PMCID: PMC5494813.

Retrospective study of Oncothermia combined with chemotherapy for the treatment of Glioblastoma. Efficiency and cost-effectiveness analysis

Retrospective study of Oncothermia combined with chemotherapy for the treatment of Glioblastoma. Efficiency and cost-effectiveness analysis

Dr. Roussakow`s Team, Department Galenic Research Institute, Moscow, Russia, recently published in the Biomedical Journal Open (BMJ Open, 2017 Nov 3; 7 (11)) the results on the complementary use of Oncothermia in Glioblastoma multiform.

Researchers compared the efficacy and cost-effectiveness of Oncothermia (electrohyperthermia mEHT) with chemotherapy (temozolomide, ddTMZ) versus chemotherapy alone in a patient with recurrent Glioblastoma multiforme (GBM).

This is a retrospective study of a population of 54 patients diagnosed with recurrent Glioblastoma multiforme treated with chemotherapy and Oncothermia (ddTMZ + mEHT) during the period 2000-2005. The comparison was made with a population of 114 patients, diagnosed with GBM, treated with chemotherapy alone (ddTMZ) during the period 2008-2013.

Results:

The treatment effect analysis (ETA) suggests that Oncothermia significantly improves the survival of patients receiving oral chemotherapy (ddTMZ). Economic evaluation suggests that ddTMZ+Oncothermia is cost-effective, budget-saving and profitable. It is derived from the results that Oncothermia can be recommended for the treatment of recurrent Glioblastoma multiforme. Oncothermia can even be assessed as monotherapy as a rescue treatment when chemotherapy fails.